Overview

Study GSI-136 in Healthy Young and Healthy Elderly Subjects

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This is a first-in-humans study of GSI-136, a drug being developed for the treatment of Alzheimer Disease. The main purpose of this study is to determine whether GSI-136 is safe and tolerable in healthy young and healthy elderly subjects. The amount of drug in the body and the effects of the drug on the body will also be evaluated at certain timepoints.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer